

Post-doctoral Fellowship (M/F)

Title of the project: FOLSMART – “Folate-Target Nanodevies To Activated Macrophages For Rheumatoid Arthritis”

Internal Reference: PR611901

We are recruiting a highly motivated postdoctoral fellow to join the Gene Regulation research group at the IBMC/i3S. The work will involve, among other tasks, the *in vitro* differentiation and activation of macrophages; to accurately model the desired biological effect of a drug in animal models, in order to predict treatment outcome in rheumatoid arthritis patients; and to assess *in vitro* the genotoxicity and toxicology of novel folate-based nanodevices.

Requirements: To be eligible for the position as postdoctoral research fellow, the applicant must have a PhD in Biomedical Sciences or similar, less than three years of post-doctoral experience, have good knowledge on Cellular and Molecular Biology and should preferentially have practical experience from previous research in cell culture and gene expression analyses, preferably evidenced by excellent publications in the field.

The applicant must be willing to work as part of an interdisciplinary and international consortium focused on working on drug/gene therapy. Finally, the applicant must be able to demonstrate excellence in written as well as spoken English.

Work plan: The successful applicant will be working within the H2020-funded FOLSMART project that brings together a multidisciplinary team of researchers from different EU Member States. The overall aim of FOLSMART is to bring to phase I clinical trials novel folate-based nanodevices for the treatment of rheumatoid arthritis (please see Abstract).

Legislation and Salary: The fellowship is regulated by current laws relating to the Statute of Science Research Fellows, namely Law 40/2004 of August 18, and the Regulation of Scientific Research Studentships of the IBMC (www.ibmc.up.pt/fellowships.php) approved by FCT. The monthly allowance is 1509.80 € (net and tax free, <http://alfa.fct.mctes.pt/apoios/bolsas/valores>).

Location: The work will be developed at the Gene Regulation laboratory of the IBMC, i3S, under the supervision of Alexandra Moreira.

Duration: 8 months, to start on the 1st of May 2019, until the end of 2019.

Selection method: The candidates will be listed according to their CV (100%) and the requirements of the call. If necessary, the pre-selected top candidates will be interviewed (interview 75% and CV 25%).

Jury: President: Alexandra Moreira (DPhil); Members: Alexandre Carmo (DPhil) and Jaime Freitas (PhD). Substitute: Isabel Pereira-Castro (PhD).

Form of notification of results: The final results of the evaluation will be publicized in the IBMC Web site, through a list sorted by final score, and the selected applicant will be notified by email.

Application deadline and submission forms: The call will be open from 3rd to 15th April 2019.

Proposals must include CV, PhD certificate, motivation letter and indication of two referees.

Applications must be done by online submission:

<http://www.ibmc.up.pt/gestaocandidaturas/index.php?codigo=PR611901>

Abstract

FOLSMART will bring to phase I clinical trials novel folate-based nanodevices (FBN) for the treatment of rheumatoid arthritis (RA). These nanodevices for folic acid (FA)-mediated targeting of activated macrophages showed improved clinical scores in a mouse model of RA when compared to methotrexate (MTX), a first-line drug therapy for the treatment of RA. In this way, FBN will be benchmarked against this drug. MTX has significant associated toxicity and second line biological therapies poses a great economic burden to hospital/public health systems. An exploitation and business plans will be elaborated. In parallel, initial economic evaluation of all proposed treatments will be performed to validate these claims.

Specific technological objectives of FOLSMART will be:

Good Manufacturing Practice (GMP) production of the FBN based therapies which have been positively bench-marked in the previous FP7 European project NANOFOL in comparison with the use of MTX in a RA mouse model:

- Liposomal MTX with FA-“neck domain” peptide as targeting agent
- Nanoparticles from HSA-FA/MTX conjugates
- Optimization of mechanisms of drug release and application to other fields

Pre-clinical development on RA models

- Toxicology and pharmacokinetics, to determine tolerability and efficacy benefit in two animal models rat and dog, under Good Laboratory Practice (GLP) standards
- Genotoxicity and Carcinogenicity

Phase I clinical trials of the best therapies bench marketed against MTX

- Nanodevices with MTX will offer improved tolerance and greater efficacy meaning that patients who do not do well on MTX will have cost-effective alternatives